International Journal of Drug Policy
Volume 16 , Pages 7-20 , December 2005

Methods for assessing HIV and HIV risk among IDUs and for evaluating interventions

  • Gerry V. Stimson

      Affiliations

    • Department of Primary Care and Social Medicine, The Centre for Research on Drugs and Health Behaviour, Imperial College, The Reynolds Building, St Dunstan's Road, London W6 8RP, UK
    • International Harm Reduction Association, PO Box 818, North Melbourne 3051, Melbourne, Vic., Australia
    • Corresponding Author InformationCorresponding author. Tel.: +44 20 7594 0776; fax: +44 20 7594 0852.
    • ,
  • Matthew Hickman

      Affiliations

    • Department of Primary Care and Social Medicine, The Centre for Research on Drugs and Health Behaviour, Imperial College, The Reynolds Building, St Dunstan's Road, London W6 8RP, UK
    • ,
  • Tim Rhodes

      Affiliations

    • Department of Primary Care and Social Medicine, The Centre for Research on Drugs and Health Behaviour, Imperial College, The Reynolds Building, St Dunstan's Road, London W6 8RP, UK
    • ,
  • Francisco Bastos

      Affiliations

    • Owaldo Cruz Foundation, Av. Brasil, 4365, Biblioteca de Manguinhos #229, 21045-900 Rio de Janeiro, Brazil
    • ,
  • Tobi Saidel

      Affiliations

    • Family Health International, Asia Regional Office, Arwan Building, 8th Floor, 1339 Pracharat 1 Road, Bangsue, Bangkok 10800, Thailand

Received 11 January 2005 ,Revised 4 February 2005 ,Accepted 6 February 2005.

References 

  1. Adelekan, M. (2000). Injection drug use and associated health consequences in Lagos, Nigeria: Findings from WHO Phase II Injection Drug Use Study. In Global research network: 2000 global research network meeting on HIV/prevention in drug-using populations. National Institute on Drug Abuse.
  2. Ades AE. Serial HIV seroprevalence surveys: Interpretation, design, and role in HIV/AIDS prediction. Journal Acquired Immune Deficiency Syndrome Human Retrovirology. 1995;9(5):490–499
  3. Asian Harm Reduction Network. (1988). The hidden epidemic: A situation assessment of drug use in South East and East Asia in the context of HIV vulnerability.
  4. Barcellos C, Bastos F. Social networks and diffusion of AIDS in Brazil. Bol Oficina Sanit Panam. 1996 July;121(1):11–24(Portuguese)
  5. Barnett A, Whiteside A, Khodakevich L, Kruglov Y, Steshenko V. The HIV/AIDS epidemic in Ukraine: Its potential social and economic impact. Social Science and Medicine. 2000;51:1387–1403
  6. Bastos F, Barcellos C, Lowndes CM, Friedman SR. Co-infection with malaria and HIV in injecting drug users in Brazil: A new challenge to public health?. Addiction. 1999;94(8):1165–1174
  7. Beyrer C, Razak MH, Lisam K, Chen J, Lui W, Yu XF. Overland heroin trafficking routes and HIV spread in south and southeast Asia. AIDS. 2000;14:1–19
  8. Booth RE, Koester SK. Issues and approaches to evaluating HIV outreach interventions. Journal of Drug Issues. 1996;26(3):525–539
  9. Bourgois P, Lettiere M, Quesada J. Social misery and the sanctions of substance use: Confronting HIV risk among homeless heroin addicts in San Francisco. Social Problems. 1997;44:155–173
  10. Broadhead RS, Heckathorn DD, Weakliem DL, Anthony DL, Madray H, Mills RJ, et al. Harnessing peer networks as an instrument for AIDS prevention: Results from a peer driven intervention. Public Health Reports. 1998;113(1):42–57
  11. Brookmeyer R, Gail MH. AIDS epidemiology: A quantitative approach. Oxford: Oxford University Press; 1994;
  12. Centers for Disease Control. (1992). Proceedings of the 1992 International Symposium on Public Health Surveillance. MMWR, 41(Suppl.).
  13. Darke S. Self-report among injecting drug users: A review. Drug and Alcohol Dependence. 1998;51(3):253–263
  14. Deaney, P. (2000). Sharing research globally on HIV among drug-using populations. In Global research network: 2000 global research network meeting on HIV/prevention in drug-using populations. National Institute on Drug Abuse.
  15. Des Jarlais DC, Dehne K, Casabona J. HIV surveillance among injecting drug users. AIDS. 2001;15(3):S13–S22
  16. Des Jarlais DC, Diaz T, Perlis T, Vlahov D, Maslow C, Latka M, et al. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. American Journal of Epidemiology. 2003;157(5):467–471
  17. Des Jarlais DC, Friedman SR, Sotheran JL, Wenston J, Marmor M, Yancovitz SR, et al. Continuity and change within an HIV epidemic: Injecting drug users in New York City, 1984 through 1992. Journal of American Medical Association. 1994;271:121–127
  18. Des Jarlais DC, Hagan H, Friedman SR, Friedmann P, Goldberg D, Frischer M, et al. Maintaining low HIV seroprevalence in populations of injecting drug users. Journal of American Medical Association. 1995;274(15):1226–1231
  19. Des Jarlais C, Perlis T, Friedman SR, Chapman T, Kwok J, Rockwell R, et al. Behavioral risk reduction in a declining HIV epidemic: Injection drug users in New York City, 1990–1997. American Journal of Public Health. 2000;90(7):1112–1116
  20. Dunn J, Laranjeira RR. HIV-risk behaviour among non-heroin using cocaine injectors and non-injectors in Sao Paulo, Brazil. AIDS Care. 2000;12(4):471–481
  21. Eicher AD, Crofts N, Benjamin S, Deutschmann P, Rodger AJ. A certain fate: Spread of HIV among young injecting drug users in Manipur, North-East India. AIDS Care. 2000;12(4):497–504
  22. Estrada AL. Drug use and HIV risks among African-American, Mexican-American, and Puerto Rican drug injectors. Journal of Psychoactive Drugs. 1998;30(3):247–253
  23. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (1997). Estimating the prevalence of problem drug use in Europe. Scientific Monograph Series No. 1. Lisbon.
  24. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (2000a). Methodological guidelines to estimate the prevalence of problem drug use at local level. CT.97.EP.05. Lisbon: EMCDDA. Available at: http://www.emcdda.org/situation/themes/problem_drug_use.shtml.
  25. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (2000b). EMCDDA Recommended Draft Technical Tools and Guidelines – Key epidemiological indicator: Prevalence of problem drug use. Lisbon. Available at: http://www.emcdda.org/situation/themes/problem_drug_use.shtml.
  26. Family Health International. (in press). Meeting the behavioural data collection needs of National HIV/AIDS and STD Programmes. A joint IMPACT/FHI/UNAIDS Workshop: Report and conclusions.
  27. Frischer M, Heatlie H. Modelling drug misuse in Europe using Geographic Information Systems. In:  Godfrey C, et al. editor. Modelling drug use: Methods to quantify and understand hidden processes. Lisbon: EMCDDA; 2001;
  28. Frischer M, Hickman M, Kraus L, Mariani F, Wiessing L. A comparison of different methods for estimating the prevalence of problematic drug misuse in Great Britain. Addiction. 2001;96:1465–1476
  29. Fry C, Dwyer R. For love or money? An exploratory study of why injecting drug users participate in research. Addiction. 2001;96(9):1319–1325
  30. Garnett GP. The basic reproductive rate of infection and the course of HIV epidemics. Aids Patient Care and STDs. 1998;12(6):435–449
  31. Global Research Network. (2000). Global research network meeting on HIV/prevention in drug-using populations. National Institute on Drug Abuse.
  32. Grassly NC, Lowndes CM, Rhodes T, Judd A, Renton A, Garnett GP. Modeling emerging HIV epidemics: The role of injecting drug use and sexual transmission in the Russian Federation, China and India. International Journal of Drug Policy. 2003;14:25–43
  33. Grund J-PC, Stern LS, Kaplan CD, Adriaans NFP, Drucker E. Drug use contexts and HIV-consequences: The effect of drug policy on patterns of everyday drug use in Rotterdam and the Bronx. British Journal of Addiction. 1992;87:41–52
  34. Harvey E, Strathdee SA, Patrick DM, Ofner M, Archibald CP, Eades G, et al. A qualitative investigation into an HIV outbreak among injection drug users in Vancouver, British Columbia. AIDS Care. 1998;10(3):313–321
  35. Heckathorn DD. Respondent-driven sampling: A new approach to the study of hidden populations. Social Problems. 1997;44(2):174–199
  36. Heckathorn DD, Semaan S, Broadhead RS, Hughes JJ. Extensions of respondent-driven sampling: A new approach to the study of injecting drug users aged 18–25. AIDS and Behaviour. 2001;6:55–67
  37. Hickman M, Taylor C, Chatterjee A, Degenhardt L, Wiessing L, Frischer M, et al. Estimating drug prevalence: Review of methods with special reference to developing countries. Bulletin of Narcotics. 2003;LIV:15–33
  38. Honti, J. (2000). Harm reduction networking in Central and Eastern Europe and the Former Soviet Union. In Global research network: 2000 global research network meeting on HIV/prevention in drug-using populations. National Institute on Drug Abuse.
  39. Hook EB, Regal RR. Capture recapture methods in epidemiology: Methods and limitations. Epidemiologic Reviews. 1995;17:243–264
  40. Hser Y, Anglin MD, Wickens TD, Brecht ML, Homer J. Techniques for the estimation of illicit drug user prevalence: An overview of relevant issues. Washington: National Institute of Justice; 1992;
  41. International Working Group for Disease Monitoring and Forecasting. Capture–recapture and multiple record systems estimation I: History and theoretical development. American Journal of Epidemiology. 1995;142:1047–1057
  42. Jenkins C, Rahman H, Saidel T, Jana S, Hussain A, Zakir M. Measuring the impact of needle exchange programs among injecting drug users through the National Behavioural Surveillance in Bangladesh. AIDS Education and Prevention. 2001;13(5):452–461
  43. Kaplan EH. Needles that kill: Modeling HIV transmission via shared drug injection equipment in shooting galleries. Reviews of Infectious Diseases. 1989;11:289–298(Erratum, 11:672, 1989)
  44. Kaplan EH, Heimer R. HIV prevalence among intravenous drug users: Model-based estimates from New Haven's Legal Needle Exchange. Journal of Acquired Immune Deficiency Syndromes. 1992;5:163–169
  45. Kumaranayake L, Watt C, Vickerman P, Walker D, Zviagin V, Samoshkin S, et al. The cost-effectiveness of HIV preventive measures among injecting drug users in Svelogorsk, Belarus. UNAIDS; 2000;
  46. Law M, Lynskey M, Ross J, Hall W. Back-projection estimates of the number of dependent heroin users in Australia. Addiction. 2001;96:433–443
  47. MacDonald M, Robotin M, Topp L. Drug use trends among injecting drug users (IDU): Findings from the Australian Needle and Syringe Program (NSP) Survey, 1995–2000. Collaboration of Australian Needle and Syringe Programs; 2001;
  48. McCoy CB, McCoy HV, Lai S, Yu Z, Wang X, Meng J. Reawakening the dragon: Changing patterns of opiate use in Asia, with particular emphasis on China's Yunnan Province. Substance Use and Misuse. 2001;36(1/2):49–69
  49. McKetin, R. (2000). Global Assessment Programme on drug abuse (GAP): United National International Drug Control Programme. In Global research network: 2000 global research network meeting on HIV/prevention in drug-using populations. National Institute on Drug Abuse.
  50. Menoyo C, Lamikiz E, Zulaika D, Urcelai A, Zubia I, De Pancorbo MM. The validation of statements by IDUs based on the analysis of blood traces on their used syringes. AIDS Care. 1998;10(4):409–414
  51. Mesquita, F. (2000). Using the WHO Multicity Study to Evaluate Harm Reduction Programs in Brazil. In Global research network: 2000 global research network meeting on HIV/prevention in drug-using populations. National Institute on Drug Abuse.
  52. Ouellet J, Jimenez A, Johnson W. Shooting galleries and HIV disease: Variations in places for injecting drugs. Crime and Delinquency. 1991;37:64–85
  53. Panda S, Chatterjee A, Bhattacharjee S, Ray B, Saha MK, Bhattacharya SK. HIV, hepatitis B and sexual practices in the street-recruited injecting drug users of Calcutta: Risk perception versus observed risks. International Journal of STD and AIDS. 1998;9(4):214–218
  54. Parsons J, Turnbull PJ, Hickman M, McSweeney T, Judd A, Roberts K, et al. Over a decade of syringe exchange: Results from 1997 UK survey. Addiction. 2002;97:845–850
  55. Rhodes T, Fitch C, Stimson GV. The rapid assessment and response guide on substance use and sexual risk behaviour (draft for field-testing). Geneva: WHO and UNAIDS; 2002;
  56. Rhodes T, Lowndes C, Judd A, Mikhailova LA, Sarang A, Rylkov A, et al. Explosive spread and high prevalence of HIV infection among injecting drug users in Togliatti City, Russia. AIDS. 2002;16:F25–F31
  57. Rodés, A., Pérez, K. (2000). Monitoratge de la prevalença i del nivell de la prevenció de la infecció per l’HIV en la comunitat d’homes homosexuals i en usuaris de drogues per via parenteral. Barcelona Generalitat de Catalunya, Departament de Sanitat i Seguretat Social. Document Tècnic CEESCAT, 11.
  58. Rossi PH, Freeman HE. Evaluation: A systematic approach. London: Sage; 1993;
  59. Saidel TJ, Des Jarlais D, Peerapatanapokin W, Dorabjee J, Singh S, Brown T. Potential impact of HIV among IDUs on heterosexual transmission in Asian settings: Scenarios from the Asian Epidemic Model. International Journal of Drug Policy. 2003;14:63–74
  60. Samson, L., & Francis, R. (2000). Are RSAs adequate for intervention development? Evidence from a multicentric RSA on injection drug use in India. In Global research network: 2000 global research network meeting on HIV/prevention in drug-using populations. National Institute on Drug Abuse.
  61. Schechter MT, Strathdee SA, Cornelisse PG, Currie S, Patrick DM, Rekart ML, et al. Do needle exchange programmes increase the spread of HIV among injection drug users? An investigation of the Vancouver outbreak. AIDS. 1999;13(6):F45–F51
  62. Stimson GV. Reconstruction of sub-regional diffusion of HIV infection among injecting drug users in South-East Asia: Implications for early intervention. Letter. AIDS. 1994;8(11):1630–1632
  63. Stimson GV. AIDS and injecting drug use in the United Kingdom, 1988–1993: The policy response and the prevention of the epidemic. Social Science and Medicine. 1995;41(5):699–716
  64. Stimson GV, Hunter GM, Donoghoe MC, Rhodes T, Parry JV, Chalmers CP. HIV-1 prevalence in community-wide samples of injecting drug users in London (1990–1993). AIDS. 1996;10(6):657–666
  65. Stimson GV, Jones S, Chalmers C, Sullivan D. A short questionnaire (IRQ) to measure injecting risk behaviour. Addiction. 1998;93(3):337–347
  66. In:  Stimson GV,  Des Jarlais DC,  Ball A editor. Drug injecting and HIV infection: Global dimensions and local responses. London: University College London Press; 1998;
  67. In:  Stimson GV,  Fitch C,  Rhodes T editor. The rapid assessment and response guide on injecting drug use (IDU-RAR) (version 5). Geneva: World Health Organization Programme on Substance Abuse; 1998;(also available in Chinese Portuguese, Russian and Spanish)
  68. Taylor A, Goldberg D, Hutchinson S, Cameron S, Fox R. High risk injecting behaviour among injectors from Glasgow: Cross sectional community wide surveys 1990–1999. Journal of Epidemiology and Community Health. 2001;55(10):766–767
  69. Taylor, C., & Hickman, M. (2002). Estimating prevalence – Indirect methods for estimating the size of the drug problem. GAP Epidemiological Toolkit Module 2. UNDCP.
  70. Tichonova L, Borisenko K, Ward H, Meheus A, Gromyko A, Renton A. Epidemics of syphilis in the Russian Federation: Trends, origins, and priorities for control. Lancet. 1997;350(9084):1100–1101
  71. Thacker SB, Berkelman RL. Public health surveillance in the United States. Epidemiologic Reviews. 1988;10:164–190
  72. Tilling K, Sterne J. Capture recapture models including covariate effects. American Journal of Epidemiology. 1999;149(4):392–400
  73. Turchi MD, Diaz RS, Martelli CM, Sabino EC, Da Silva WP, Filho OF, et al. Genetic diversity and HIV-1 incidence estimation among cocaine users in Sao Paulo, Brazil. Journal of Acquired Immune Deficiency Syndrome. 2002;30(5):527–532
  74. Turnbull PJ, Power R, Stimson GV. “Just using old works”: Injecting risk behaviour in prison. Drug and Alcohol Review. 1996;15:251–260
  75. United Nations Office for Drug Control and Crime Prevention. GAP: Global assessment programme on drug abuse: Overview and update 2000–2001. 2001;
  76. Valenciano M, Emmanuelli J, Lert F. Unsafe injecting practices among attendees of syringe exchange programmes in France. Addiction. 2001;96(4):597–606
  77. Van Ameijden E, Coutinho R. Maximum impact of HIV prevention measures targeted at injecting drug users. AIDS. 1998;12:625–634
  78. Van Ameijden EJ, Langendam MW, Notenboom J, Coutinho RA. Continuing injecting risk behaviour: Results from the Amsterdam Cohort Study of drug users. Addiction. 1999;94(7):1051–1061
  79. Van Ameijden EJ, Van den Hoek JA, Mientjes GH, Coutinho RA. A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. European Journal Epidemiology. 1993;9(3):255–262
  80. Vickerman P, Watts C. The impact of an HIV prevention intervention for injecting drug users in Svelogorsk, Belarus: Model predictions. International Journal of Drug Policy. 2002;13(3):149–164
  81. Walker N, Garcia-Calleja JM, Heaton L, Asamoah-Odei E, Poumerol G, Lazzari S, et al. Epidemiological analysis of the quality of HIV sero-surveillance in the world: How well do we track the epidemic?. AIDS. 2001;15:1545–1554
  82. Wiebel W. Ethnographic contributions to AIDS intervention strategies. In:  Rhodes T,  Hartnoll R editor. AIDS, drugs and prevention: Perspectives on individual and community action. London: Routledge; 1996;p. 186–200
  83. Wiessing, L. (2000). Estimating coverage of harm-reduction measures for injection drug users in Europe. In Global research network: 2000 global research network meeting on HIV/prevention in drug-using populations. National Institute on Drug Abuse.
  84. World Health Organization and Joint United Nations Programme on HIV/AIDS. (2000). Guidelines for second generation HIV surveillance. Geneva, Switzerland. WHO/CDS/CSR/EDC/2000.5 & UNAIDS/00.03E.
  85. Wu Z. Recent trends of injection drug use and related HIV infection in China. In: Presented at the Global Research Network Meeting on HIV Prevention in Drug-Using Populations. Geneva, 25–26 June. 1998;p. 81–86
  86. Wu Z, Zhang J, Detels R, Li VC, Cheng H, Duan S, et al. Characteristics of risk-taking behaviors, HIV and AIDS knowledge, and risk perception among young males in southwest China. AIDS Education and Prevention. 1997;9(2):147–160

PII: S0955-3959(05)00083-6

doi: 10.1016/j.drugpo.2005.02.007

International Journal of Drug Policy
Volume 16 , Pages 7-20 , December 2005

Article Tools

* Image Usage & Resolution